GENE ONLINE|News &
Opinion
Blog

2025-11-27|

Re-Emergence of Tardive Dyskinesia Observed in Nutritional Rehabilitation for Atypical Anorexia Nervosa

by GOAI
Share To

A recent case study has identified the re-emergence of tardive dyskinesia in individuals undergoing nutritional rehabilitation for atypical anorexia nervosa. Researchers Gulino, Reardon, and Johnson documented cases where patients recovering from atypical anorexia experienced involuntary movements associated with tardive dyskinesia, a neurological disorder often linked to long-term use of certain medications. The findings suggest a potential connection between the recovery process and the resurfacing of this condition.

The study examined patients diagnosed with atypical anorexia nervosa who were undergoing treatment aimed at restoring nutritional balance. During recovery, some individuals exhibited symptoms consistent with tardive dyskinesia, including repetitive and uncontrollable movements. Tardive dyskinesia is typically associated with prolonged exposure to antipsychotic medications; however, its appearance during anorexia recovery raises questions about underlying mechanisms or contributing factors related to nutritional changes or treatment protocols. Researchers aim to further investigate these occurrences to better understand their implications for patient care during recovery from eating disorders.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top